The preclinical research also found that delivering the CAR T cell therapy via an injection where the cancer is located, regionally, is also effective in enabling CAR T cells to target cancer elsewhere. This technology allows for both safety and improved anti-tumor activity in several cancer types...
T cellsChimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of malignancies, especially hematological tumors, but toxicities have tempered its success. The main impediments to the development of CAR-T cell therapies are the following: cytokine release syndrome (C...
6.Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023;141(20):2460-9. 7.Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, et al. Hematopoietic recovery in pat...
where we have a generic CAR-T cell. The specificity is only given by the adapter molecule. We can exchange the adapter and thereby target multiple antigens, either in parallel or sequentially. So I think the big ad...
A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer
Chimeric antigen receptor (CAR)-T cell adoptive immunotherapy is a promising cancer treatment that uses genetically engineered T cells to attack tumors. However, this therapy can have some adverse effects. CAR-T cell-derived exosomes are a potential alte
LOS ANGELES, April 23 (Xinhua) -- An advance in the breakthrough cancer treatment known as CAR T-cell therapy appears to eliminate its severe side effects, making the treatment safer and potentially available in outpatient settings, according to a new study of the University of Southern Californ...
Chimeric antigen receptor (CAR)-T cell adoptive immunotherapy is a promising cancer treatment that uses genetically engineered T cells to attack tumors. However, this therapy can have some adverse effects. CAR-T cell-derived exosomes are a potential alte
A novel CAR T-cell therapy, developed by UCL researchers and designed to target cancer cells more quickly and cause fewer side effects, has shown very promising results for children with previously incurable acute lymphoblastic leukemia (ALL).
CMS has proposed a different way to handle payment for chimeric antigen receptor T-cell therapy, one that the medical and manufacturing community thinks is unworkable.